A phase Ib/II study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R/R CLL/SLL).

Li, JY; Zhou, KS; Nian, WQ; Cui, GH; Wang, JS; Zhang, XP; Cen, H; Li, F; Yi, SH; Feng, R; Xu, CY; Qian, WB; Liu, LH; Li, CX; Zhao, XL; Chen, Z; Qiao, JX; Zhang, HL; Ahmad, M; Zhai, YF

JOURNAL OF CLINICAL ONCOLOGY, 2022; 40 (16):

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索